Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia

Vasa - Journal of Vascular Diseases

Volumn 39, Issue 1, 2010, Pages 33-41

  Heidrich, H ^a  

^a NONE

Author keywords

Acrocyanosis; Erythromelalgia; Functional vascular diseases; Raynaud's phenomenon; Raynaud's syndrome

Indexed keywords

ACETYLSALICYLIC ACID; INDOMETACIN; MISOPROSTOL; PLACEBO;

ACROCYANOSIS; CLINICAL FEATURE; CLINICAL TRIAL; COLD; ERYTHROMELALGIA; EUROPE; HUMAN; RARE DISEASE; RAYNAUD PHENOMENON; REVIEW; SEX DIFFERENCE; STRESS; THROMBOCYTHEMIA; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; ERYTHROMELALGIA; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; MALE; MIDDLE AGED; RAYNAUD DISEASE; SEX RATIO; VASCULAR DISEASES;

EID: 77749298326     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000003     Document Type: Review

References (53)

1. Al-Awami M, Schillinger M, Minar E: Vasospasm of the scrotum - a manifestation of Raynaud's phenomenon? VASA 2004; 33: 87-8.
2. Amblard P: Vraies et fausses acrocyanoses. Rev Prat 1998; 48: 1665-8.
3. Anderson JE, Held N, Wright K: Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. Pediatrics 2004; 113: 360-4.
4. Belch JJ: Temperature - associated vascular disorders: Raynaud's phenomenon and Erythromelalgia. In: Tooke JE, Lowe GDO (eds) A textbook of vascular medicine. Arnold, London, 1996: 342-52.
5. Blunt RJ, Porter JM: Raynaud Syndrome Sem Arthritis and Rheumatism, 1981; 10: 282-308.
6. Bridges MJ, Kelly CA: Raynaud's phenomenon affecting the tongue of a patient with scleroderma. Ann Rheum Dis 2002; 61: 472.
7. Brown KM, Middaugh SJ, Hay thornthwaite JA et al.: The Effects of Stress, Anxiety, and Outdoor Temperature on the Frequency and Severity of Raynaud's Attacks: The Raynaud's Treatment Study J Behav Medic 2001; 24: 137-53.
8. Cohen JS: Erythromelalgia. New theories and new therapies, J Am Acad Dermatol 2000; 43: 841-7.
9. Davis MD, O'Fallon WM, Rogers RS 3rd, Rooke TW: Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol 2000; 136: 330-6.
10. Davis MD, Sandroni P, Rooke TW, Low PA: Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia. Arch. Dermatol, 2003; 139: 1337-43.
11. Davis MD, Rooke T: Erythromelalgia. Curr Treat Options Cardiovasc Med 2006; 8: 153-65.
12. Davis MD, Weenig RH, Genebriera J et al.: Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density. J Am Acad Dermatol2006; 55: 519-22.
13. Diogenes MJ, Diogenes PC, de Morais-Carneiro RM, et al: Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol 2004; 43: 632-7.
14. Distler M, Distler J, Ciurea A, et al.: Evidenzbasierte Therapie des Raynaud-Syndroms. Rheumatol 2006; 65: 285-9.
15. Drenth JP, Vuzevski V, Van Joost T, et al: Cutaneous pathology in primary erythermalgia. Am J dermatopathol 1996: 18: 30-4.
16. Drenth JP, Finley WH, Breedveld GJ, et al: The primary erythermalgia-suspectibility gene is located on chromosome 2q31-32. A J human genetics; 2001; 68: 1277-82
17. Durosaro O, Davis MD, Hooten WM, et al.: Intervention for erythromelalgia, a chronic pain syndrome: comprehensive pain rehabilitation center, Mayo Clinic. Arch Dermatol 2008; 144: 1578-83.
18. Fitzgerald O, Hess EV, O'Connor GT, et al.: Prospective Study of the Evolution of Raynaud's Phenomenon. Am J Med 1988; 84: 718-26.
19. Garrison CP: Nipple vasospasms, Raynaud's syndrome, and nifedipine. J Hum Lact 2002; 18: 382-5.
20. Gerbracht DD, Steen VD, Ziegler GL, et al.: Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum, 1985; 28: 87-92.
21. Harper FE, Maricq HR, Turner RE, et al.: A Prospective Study of Raynaud Phenomenon and Early Connective Tissue Disease. A Five-Year Report. Am J Med (1982); 72: 833-88.
22. Heidrich H: Definition und Terminologie von Raynaud-Syndromen. Dtsch Med Wochenschr 2008; 133: 1742-3.
23. Heidrich H, Helmis J, Fahrig C, et al.: Clinical Characteristics of Primary, Secondary and Suspected Secondary Raynaud's Syndrome and Diagnostic Transition in the Long-Term Follow-Up VASA 2008; S 73: 3-25.
24. Hirschl M, Hirschl K, Lenz M, et al.: Transition From Primary Raynaud's Phenomenon to Secondary Raynaud's Phenomenon Identified by Diagnosis of an Associated Disease. Results of Ten Years of Prospective Surveillance Arthritis & Rheumatism 2006: 54: 1974-81.
25. Jones GT, Herrick AL, Woodham SAE, et al.: Occurrence of Raynaud's Phenomenon. in Children Ages 12-15 Years. Prevalence and Association With Other Common Symptoms Arthritis & Rheumatism 2003; 48: 3518-21.
26. Kalgaard OM, Mork C, Kvernebo K: Prostacyclin reduces symptoms and sympathethic dysfunction in erythromelalgia in a double-blind randomized pilot study. Acta Derm Venereol 2003; 83: 442-4.
27. Kallenberg CGM: Systemic autoimmune disease and Raynaud's phenomenon. Drukkerij Van Denderen B.V., Groningen, 1982.
28. Kallenberg CG: Early detection of connective tissue disease in patients with Raynaud's phenomenon Rheum Dis Clin North Am 1990; 16: 11-30.
29. Klein-Weigel P: Paraneoplasti sche akrale Durchblutungsstörungen - eine diagnostische Herausforderung. Vasomed 2003; 15: 184-6.
30. Klein-Weigel P, Rein P, Kronenberg F, et al.: Microcirculatory assessment of vascular acrosyndrome in anorexia nervosa and analysis of manifestation factors, J Psychosom Res 2004; 56: 145-8.
31. Klein-Weigel P, Olges K, Wolbergs S, et al.: Behandlung der Erythromelalgie mit aktivem Weinkühler und Amitriptylin-Ketamin-Gel. Fallbericht mit aktueller Literaturübersicht. Phle bologie 2007; 36: 151-5.
32. Kropman RF: Raynaud's Phenomenon of the Penis. J Urol, 2004; 171: 1630.
33. Lazareth I, Delarue R, Priolett P: Quand évoquer un syndrome myeloproliferatif en pathologie vasculaire? J Mal Vasc 2005; 30: 46-52.
34. Ljubojevic S, Lipozencic J, Pustisek N: Erythromelalgia. Acta Dermatovenerol Croat 2004; 12: 99-105.
35. Metin K, Karacelik M, Yavaccan O, Celik M, Dorak MC, Oto O, Aksu N: Surgical treatment of pulmonary arterio-venous malformation: report of two cases and review of the literature. J Int Med Res 2005; 33: 467-71.
36. Michiels JJ: Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirinresponsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. Pathol Biol (Paris) 2003; 51: 167-75.
37. Monticone G, Colonna L, Palermi G, et al.: Quantitative nailfold capillary microscopy findings in patients with acrocyanosis compared with patients having systemic sclerosis and control subjects. J Am Acad Dermatol 2000; 42: 787-90.
38. 1 analog misoprostol reduced symptoms and microvascular arteriovenous shunting in erythromelalgia - a doubleblind, crossover, placebo- compared study. J Invest Dermatol 2004; 122: 587-93.
39. Müller-Ladner U: Raynaud-Syndrom und akrale Ischämiesyndrome. UNI-MED Verlag, Bremen, 2006.
40. Nigrovic PA, Fuhlbrigge RC, Sundel RP: Raynaud's Phenomen in Children: A Retrospective Review of 123 Patients. Pediatrics 2003; 111: 715-21.
41. Paticoff J, Valovska A, Nedeljkovic SS, et al.: Defining a treatable cause of erythromelalgia: acute adolescent autoimmune small-fiber axonopathy. Anesth Analg 2007; 104: 438-41.
42. Planchon B, Becker F, Carpentier PH, et al.: Acrocyanose, évolution des concepts et limites nosologiques. J Mal Vasc 2001; 26: 5-15.
43. Porciello G, Scarpato R, Ferri C, et al.: Spontaneous Chromosome Damage (Micronuclei) in Systemic Sclerosis and Raynaud's Phenomenon J Rheumatol 2003; 30: 1244-7.
44. Poszepczynska-Guigne E, Vigu ier M, Chosidow O, et al.: Paraneoplastic acral vascular syndrome: epidemiologic features, clinical manifestations, and disease sequelae. J Am Acad Dermatol2002; 47: 47-52.
45. Priollet P, Vayssairat M, Housset E: How to classify Raynaud's phenomenon Amer J Med 1987; 83: 494-8.
46. Sagher F, Davis E, Sheskin J, Landau J: The small blood vessels of the skin in acrocyanosis. Comparison of biomicroscopy and biopsy findings. Br J Dermatol 1966; 78: 586-9.
47. Schlattmann P, Höhne J, Plümper M, et al.: The association of Raynaud's phenomenon / syndro me with scleroderma and Sjögren's syndrome - a meta-analysis. VASA 2008; S 73: 26-32.
48. Spencer-Green G: Outcomes in Primary Raynaud Phenomenon. A Meta-analysis of the Frequency, Rates, and Predictors of Transition to Secondary Diseases Arch Intern Med 1998; 158: 595-600.
49. Stammler F, Lawall H, Diehm C: Repeated attacks of pain in the nipple of a pregnant woman. Unusual manifestation of Raynaud's phenomenon. Dtsch Med Wochenschr 2003; 128: 1825-8.
50. Sunderkötter C, Riemekasten G: Raynaud-Phänomen in der Dermatologie. Hautarzt 2006; 57: 927-42.
51. Waxmann SG, Dib-Hajj SD, Erythromelalgia: a hereditary pain syndrome enters the modular era. Ann Neurol 2005; 57: 785-8.
52. Weigel I, Klein-Weigel P, Kinzl J, et al.: Psychiatrische Untersuchungen Tiroler Patienten mit primärem Raynaud-Syndrom. Wien Med Wochenschr 2005; 155: 416-21.
53. Ziegler S, Brunner M, Eigenbauer E, et al.: Long term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis Scand J Rheumatol 2003; 32: 343-7.